Cytoagents INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersAllegheny, PA
SAM.gov UEICCEZCKNKL9M4
CytoAgents is developing CTO1681, a therapeutic compound for treating pulmonary arterial hypertension, asthma, atopic dermatitis, and inflammation in the tumor microenvironment. The compound is designed as an oral immunomodulator targeting dysregulated cytokine signaling and immune hyperactivation across inflammatory and oncology indications.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Cytoagents INC | Allegheny | PA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.


